Format

Send to

Choose Destination
See comment in PubMed Commons below
Am J Trop Med Hyg. 2013 Feb;88(2):216-21. doi: 10.4269/ajtmh.11-0812.

Drug discovery algorithm for cutaneous leishmaniasis.

Author information

1
Division Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA. max.grogl1@us.army.mil

Abstract

Cutaneous leishmaniasis is clinically widespread but lacks treatments that are effective and well tolerated. Because all present drugs have been grandfathered into clinical use, there are no examples of a pre-clinical product evaluation scheme that lead to new candidates for formal development. To provide oral agents for development targeting cutaneous leishmaniasis, we have implemented a discovery scheme that incorporates in vitro and in vivo testing of efficacy, toxicity, and pharmacokinetics/metabolism. Particular emphasis is placed on in vivo testing, progression from higher-throughput models to those with most clinical relevance, and efficient use of resources.

PMID:
23390221
PMCID:
PMC3583307
DOI:
10.4269/ajtmh.11-0812
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Ingenta plc Icon for PubMed Central
    Loading ...
    Support Center